Tag «BMS»

Tasimelteon, タシメルテオン

It’s only fair to share… Tasimelteon N-([(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl)propanamide, 609799-22-6 [RN] 8985 Hetlioz [Trade name] N-{[(1R,2R)-2-(2,3-Dihydro-1-benzofuran-4-yl)cyclopropyl]methyl}propanamide [ACD/IUPAC Name] Propanamide, N-[[(1R,2R)-2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]- [ACD/Index Name] SHS4PU80D9 609799-22-6 cas, BMS-214778; VEC-162, ATC:N05CH03 Use:Treatment of sleep disorder; Melatonin receptor agonist (1R,2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide Formula:C15H19NO2, MW:245.3 g/mol Hetlioz Vanda Pharmaceuticals, 2014 Approved fda 2014 EMA Tasimelteon is a white to off-white crystalline powder, it is non hygroscopic, soluble in water across relevant …

BMS-986020

It’s only fair to share… BMS-986020 AM-152; BMS-986020; BMS-986202 cas 1257213-50-5 Chemical Formula: C29H26N2O5 Molecular Weight: 482.536 (R)-1-(4′-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid Cyclopropanecarboxylic acid, 1-(4′-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1′-biphenyl)-4-yl)- 1-(4′-(3-Methyl-4-(((((R)-1-phenylethyl)oxy)carbonyl)amino)isoxazol-5-yl)biphenyl-4-yl)cyclopropanecarboxylic acid UNII: 38CTP01B4L For treatment for pulmonary fibrosis, phase 2, The lysophosphatidic acid receptor, LPA1, has been implicated as a therapeutic target for fibrotic disorders Lysophospholipids (LPs), including lysophosphatidic acid (LPA), sphingosine 1-phospate (S1P), …

BMS 906024

It’s only fair to share… BMS 906024 cas 1401066-79-2 MF C26H26F6N4O3 MW 556.500 (2R,3S)-N-[(3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)succinamide Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)- (2R,35)-N-((35)-l-Methyl-2-oxo-5-phenyl-2,3-dihydro-lH-l,4-benzodiazepin-3-yl)-3- (2,2,2-trifluoroethyl)-2-(3,3,3-trifluoropropyl)succinamide Claude Quesnelle, Soong-Hoon Kim, Francis Lee, Ashvinikumar Gavai Applicant Bristol-Myers Squibb Company Ashvinikumar Gavai   Claude Quesnelle Senior Research Investigator/Chemist at Bristol-Myers Squibb RICHARD LEE BMS-906024 is a novel, potent Notch receptor inhibitor . Cancers have a tendency …